The advent of early Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) screening has increased the elimination rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and why it has become so important in drug discovery and development. Assays that have been developed in response to specific needs, and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of toxicity, are discussed. The paper concludes with the authors’ forecast of new models that will better predict human efficacy and toxicity.
KaitinK.I. (2008). Obstacles and opportunities in new drug development. Clinical Pharmacology & Therapeutics83, 210–212.
2.
DiMasiJ.A., HansenR.W. & GrabowskiH.G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics22, 151–185.
3.
KolaI. & LandisJ. (2004). Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery3, 711–715.
4.
HonigP.K., WoosleyR.L., ZamaniK., ConnerD.P. & CantilenaL.R. (1992). Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant admin istration of erythromycin. Clinical Pharmacology & Therapeutics52, 231–238.
5.
HonigP.K., WorthamD.C., ZamaniK., ConnerD.P., MullinJ.C. & CantilenaL.R. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. Journal of the American Medical Association269, 1513–1518.
6.
FDA (1998). Seldane and generic terfenadine with-drawn from market. FDA Talk Paper T98-10. Available at: http://www.fda.gov/bbs/topics/answers/ans00853.html (Accessed 07.04.09). Rockville, MD, USA: Food and Drug Administration, US Department of Health and Human Services.
7.
BallP., MandellL., NikiY. & TillotsonG. (1999). Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety21, 407–421.
8.
FDA (1999). Public Health Advisory: Trovan (trovafloxacin/alatroflocacin mesylate). 9th June 1999. Available at: http://www.fda.gov/cder/news/trovan/ (Accessed 07.04.09). Rockville, MD, USA: Food and Drug Administration, US Department of Health and Human Services.
KubinyiH. (2003). Drug research: myths, hype and reality. Nature Reviews Drug Discovery2, 665–668.
11.
SchusterD., LaggnerC. & LangerT. (2005). Why drugs fail — a study on side effects in new chemical entities. Current Pharmaceutical Design11, 3545–3559.
12.
LipinskiC.A., LombardoF., DominyB.W. & FeeneyP.J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews23, 3–25.
13.
LipinskiC.A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological & Toxicological Methods44, 235–249.
14.
OlsonH., BettonG., RobinsonD., ThomasK., MonroA., KolajaG., LillyP., SandersJ., SipesG., BrackenW., DoratoM., Van DeunK., SmithP., BergerB. & HellerA. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology & Pharmacology32, 56–67.
15.
FDA (1997). Guidance for Industry. Drug metabolism/drug interaction: studies in vitro. Available at: http://www.fda.gov/cder/guidance/clin3.pdf (Accessed 07.04.09). Rockville, MD, USA: Centre for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services.
16.
UetrechtJ. (2008). Idiosyncratic drug reactions: past, present, and future. Chemical Research in Toxicology21, 84–92.
17.
DykensJ.A. & WillY. (2007). The significance of mitochondrial testing in drug development. Drug Discovery Today12, 777–785.
18.
Rodríguez-EnríquezS., JuárezO., Rodríguez-ZavalaJ.S., & Moreno-SánchezR. (2001). Multisite control of the Crabtree effect in ascites hepatoma cells. European Journal of Biochemistry268, 2512–2519.
19.
MarroquinL.D., HynesJ., DykensJ.A., JamiesonJ.D. & WillY. (2007). Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicological Sciences97, 539–547.
20.
WilliamsD.P. & ParkB.K. (2003). Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discovery Today8, 1044–1050.
21.
LiuZ.X. & KaplowitzN. (2006). Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opinion on Drug Metabolism & Toxicology2, 493–503.
22.
AdemuyiwaO., AgarwalR., ChandraR. & BehariJ.R. (2009). Lead-induced phospholipidosis and cholesterogenesis in rat tissues. Chemical & Biological Interactions179, 314–320.
23.
MesensN., SteemansM., HansenE., PetersA., VerheyenG. & VanparysP. (2009). A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicology in Vitro23, 217–226.
24.
FDA (1997). Guidance for Industry. S2B genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals. Available at: http://www.fda.gov/cder/guidance/1856fnl.pdf (Accessed 07.04.09). Rockville, MD, USA: Centre for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services.
25.
HastwellP.W., ChaiL-L., RobertsK.J., WebsterT.W., HarveyJ.S., ReesR.W. & WalmsleyR.M. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutation Research607, 160–175.
26.
KhetaniS.R. & BhatiaS.N. (2008). Microscale culture of human liver cells for drug development. Nature Biotechnology26, 120–126.
27.
ViravaidyaK. & ShulerM.L. (2004). Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnology Progress20, 590–597.
28.
YangL., SoonpaaM.H., AdlerE.D., RoepkeT.K., KattmanS.J., KennedyM., HenckaertsE., BonhamK., AbbottG.W., LindenR.M., FieldL.J. & KellerG.M. (2008). Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature, London453, 524–529.
29.
O'BrienP.J., IrwinW., DiazD., Howard-CofieldE., KrejsaC.M., SlaughterM.R., GaoB., KaludercicN., AngelineA., BernardiP., BrainP. & HoughamC. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Archives of Toxicology80, 580–604.
30.
StoughtonR.B. & FriendS.H. (2005). How molecular profiling could revolutionize drug discovery. Nature Reviews. Drug Discovery4, 345–350.
31.
KaplowitzN. (2005). Idiosyncratic drug hepatotoxicity. Nature Reviews. Drug Discovery4, 489–499.
32.
EkinsS., NikolskyY. & NikolskayaT. (2005). Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends in Pharmacological Sciences26, 202–209.
